Developer tools

Rule library

External JSON rules used by the canonical PGx engine, including generated ClinPGx-backed PGx rules and local fallback rules.

Coverage matrix Source registry

ClinPGx import status

Generated rules are local JSON artifacts. Patient evaluation does not call ClinPGx live.

Last sync

2026-05-15T13:30:10.585Z

Generated PGx rules

Needs review

Active local fallback

Superseded local

Rules

168 scoring and safety rules loaded. Generated ClinPGx-backed PGx rules are loaded before active local fallback PGx rules.

Rule	Layer	Origin	Drug/Class	Source	Source object	Review	Impact	Explanation
clinpgx_amitriptyline_cyp2c19_poor_guideline_high_fixture_cpic_tca_cyp2c19_amitriptyline_pm	pgx	ClinPGx generated	amitriptyline	clinpgx_guideline_high high	fixture-cpic-tca-cyp2c19-amitriptyline-pm guideline_annotation	-	clinical_review_required	CYP2C19 poor metabolizer status contributed a source-backed PGx review signal for Amitriptyline in this educational prototype.
clinpgx_amitriptyline_cyp2d6_poor_guideline_high_fixture_cpic_tca_cyp2d6_amitriptyline_pm	pgx	ClinPGx generated	amitriptyline	clinpgx_guideline_high high	fixture-cpic-tca-cyp2d6-amitriptyline-pm guideline_annotation	-	use_with_caution	CYP2D6 poor metabolizer status contributed a source-backed PGx review signal for Amitriptyline in this educational prototype.
clinpgx_bupropion_cyp2b6_poor_clinical_annotation_fixture_clinical_bupropion_cyp2b6_pm	pgx	ClinPGx generated	bupropion	clinpgx_clinical_annotation moderate	fixture-clinical-bupropion-cyp2b6-pm clinical_annotation	-	reasonable_with_monitoring	CYP2B6 poor metabolizer status contributed a source-backed PGx review signal for Bupropion in this educational prototype.
clinpgx_citalopram_cyp2c19_poor_guideline_high_fixture_cpic_sri_cyp2c19_citalopram_pm	pgx	ClinPGx generated	citalopram	clinpgx_guideline_high high	fixture-cpic-sri-cyp2c19-citalopram-pm guideline_annotation	-	use_with_caution	CYP2C19 poor metabolizer status contributed a source-backed PGx review signal for Citalopram in this educational prototype.
clinpgx_citalopram_cyp2c19_rapid_guideline_moderate_fixture_cpic_sri_cyp2c19_citalopram_rapid	pgx	ClinPGx generated	citalopram	clinpgx_guideline_moderate moderate	fixture-cpic-sri-cyp2c19-citalopram-rapid guideline_annotation	-	reasonable_with_monitoring	CYP2C19 rapid metabolizer status contributed a source-backed PGx review signal for Citalopram in this educational prototype.
clinpgx_citalopram_cyp2c19_ultrarapid_guideline_high_fixture_cpic_sri_cyp2c19_citalopram_um	pgx	ClinPGx generated	citalopram	clinpgx_guideline_high high	fixture-cpic-sri-cyp2c19-citalopram-um guideline_annotation	-	consider_alternative	CYP2C19 ultrarapid metabolizer status contributed a source-backed PGx review signal for Citalopram in this educational prototype.
clinpgx_duloxetine_cyp2d6_poor_clinical_annotation_fixture_clinical_duloxetine_cyp2d6_pm	pgx	ClinPGx generated	duloxetine	clinpgx_clinical_annotation moderate	fixture-clinical-duloxetine-cyp2d6-pm clinical_annotation	-	reasonable_with_monitoring	CYP2D6 poor metabolizer status contributed a source-backed PGx review signal for Duloxetine in this educational prototype.
clinpgx_escitalopram_cyp2c19_poor_guideline_high_fixture_cpic_sri_cyp2c19_escitalopram_pm	pgx	ClinPGx generated	escitalopram	clinpgx_guideline_high high	fixture-cpic-sri-cyp2c19-escitalopram-pm guideline_annotation	-	use_with_caution	CYP2C19 poor metabolizer status contributed a source-backed PGx review signal for Escitalopram in this educational prototype.
clinpgx_escitalopram_cyp2c19_ultrarapid_guideline_high_fixture_cpic_sri_cyp2c19_escitalopram_um	pgx	ClinPGx generated	escitalopram	clinpgx_guideline_high high	fixture-cpic-sri-cyp2c19-escitalopram-um guideline_annotation	-	consider_alternative	CYP2C19 ultrarapid metabolizer status contributed a source-backed PGx review signal for Escitalopram in this educational prototype.
clinpgx_fluoxetine_cyp2d6_poor_clinical_annotation_fixture_clinical_fluoxetine_cyp2d6_pm	pgx	ClinPGx generated	fluoxetine	clinpgx_clinical_annotation moderate	fixture-clinical-fluoxetine-cyp2d6-pm clinical_annotation	-	reasonable_with_monitoring	CYP2D6 poor metabolizer status contributed a source-backed PGx review signal for Fluoxetine in this educational prototype.
clinpgx_fluvoxamine_cyp2d6_poor_pathway_fixture_pathway_fluvoxamine_cyp2d6	pgx	ClinPGx generated	fluvoxamine	clinpgx_pathway low	fixture-pathway-fluvoxamine-cyp2d6 pathway	review required	score delta	CYP2D6 poor metabolizer status contributed a source-backed PGx review signal for Fluvoxamine in this educational prototype. This generated rule requires human review before use outside educational testing.
clinpgx_imipramine_cyp2c19_poor_guideline_high_fixture_cpic_tca_cyp2c19_imipramine_pm	pgx	ClinPGx generated	imipramine	clinpgx_guideline_high high	fixture-cpic-tca-cyp2c19-imipramine-pm guideline_annotation	-	clinical_review_required	CYP2C19 poor metabolizer status contributed a source-backed PGx review signal for Imipramine in this educational prototype.
clinpgx_imipramine_cyp2d6_poor_guideline_high_fixture_cpic_tca_cyp2d6_imipramine_pm	pgx	ClinPGx generated	imipramine	clinpgx_guideline_high high	fixture-cpic-tca-cyp2d6-imipramine-pm guideline_annotation	-	use_with_caution	CYP2D6 poor metabolizer status contributed a source-backed PGx review signal for Imipramine in this educational prototype.
clinpgx_mirtazapine_cyp2d6_poor_pathway_fixture_pathway_mirtazapine_cyp2d6	pgx	ClinPGx generated	mirtazapine	clinpgx_pathway low	fixture-pathway-mirtazapine-cyp2d6 pathway	review required	score delta	CYP2D6 poor metabolizer status contributed a source-backed PGx review signal for Mirtazapine in this educational prototype. This generated rule requires human review before use outside educational testing.
clinpgx_nortriptyline_cyp2d6_poor_guideline_high_fixture_cpic_tca_cyp2d6_nortriptyline_pm	pgx	ClinPGx generated	nortriptyline	clinpgx_guideline_high high	fixture-cpic-tca-cyp2d6-nortriptyline-pm guideline_annotation	-	use_with_caution	CYP2D6 poor metabolizer status contributed a source-backed PGx review signal for Nortriptyline in this educational prototype.
clinpgx_paroxetine_cyp2d6_poor_clinical_annotation_fixture_clinical_paroxetine_cyp2d6_pm	pgx	ClinPGx generated	paroxetine	clinpgx_clinical_annotation moderate	fixture-clinical-paroxetine-cyp2d6-pm clinical_annotation	-	use_with_caution	CYP2D6 poor metabolizer status contributed a source-backed PGx review signal for Paroxetine in this educational prototype.
clinpgx_sertraline_cyp2b6_poor_guideline_moderate_fixture_cpic_sri_cyp2b6_sertraline_pm	pgx	ClinPGx generated	sertraline	clinpgx_guideline_moderate moderate	fixture-cpic-sri-cyp2b6-sertraline-pm guideline_annotation	-	reasonable_with_monitoring	CYP2B6 poor metabolizer status contributed a source-backed PGx review signal for Sertraline in this educational prototype.
clinpgx_sertraline_cyp2c19_poor_guideline_moderate_fixture_cpic_sri_cyp2c19_sertraline_pm	pgx	ClinPGx generated	sertraline	clinpgx_guideline_moderate moderate	fixture-cpic-sri-cyp2c19-sertraline-pm guideline_annotation	-	reasonable_with_monitoring	CYP2C19 poor metabolizer status contributed a source-backed PGx review signal for Sertraline in this educational prototype.
clinpgx_sertraline_cyp2c19_ultrarapid_guideline_moderate_fixture_cpic_sri_cyp2c19_sertraline_um	pgx	ClinPGx generated	sertraline	clinpgx_guideline_moderate moderate	fixture-cpic-sri-cyp2c19-sertraline-um guideline_annotation	-	reasonable_with_monitoring	CYP2C19 ultrarapid metabolizer status contributed a source-backed PGx review signal for Sertraline in this educational prototype.
clinpgx_venlafaxine_cyp2d6_poor_clinical_annotation_fixture_clinical_venlafaxine_cyp2d6_pm	pgx	ClinPGx generated	venlafaxine	clinpgx_clinical_annotation moderate	fixture-clinical-venlafaxine-cyp2d6-pm clinical_annotation	-	clinical_review_required	CYP2D6 poor metabolizer status contributed a source-backed PGx review signal for Venlafaxine in this educational prototype.
clinpgx_vortioxetine_cyp2d6_poor_label_fixture_label_vortioxetine_cyp2d6_pm	pgx	ClinPGx generated	vortioxetine	clinpgx_label high	fixture-label-vortioxetine-cyp2d6-pm drug_label	-	use_with_caution	CYP2D6 poor metabolizer status contributed a source-backed PGx review signal for Vortioxetine in this educational prototype.
pgx_citalopram_cyp2c19_im_v1	pgx	local fallback	citalopram	cpic_sri_2023 moderate	-	-	reasonable_with_monitoring	CYP2C19 intermediate metabolism modestly increases exposure uncertainty.
pgx_escitalopram_cyp2c19_im_v1	pgx	local fallback	escitalopram	cpic_sri_2023 moderate	-	-	reasonable_with_monitoring	CYP2C19 intermediate metabolism modestly increases exposure uncertainty.
pgx_sertraline_cyp2c19_intermediate_v1	pgx	local fallback	sertraline	cpic_sri_2023 moderate	-	-	reasonable_with_monitoring	CYP2C19 intermediate metabolism modestly increases exposure uncertainty.
pgx_sertraline_cyp2c19_rapid_v1	pgx	local fallback	sertraline	cpic_sri_2023 low	-	-	reasonable_with_monitoring	CYP2C19 rapid metabolism may lower exposure in the pathway model.
pgx_sertraline_cyp2b6_intermediate_v1	pgx	local fallback	sertraline	cpic_sri_2023 moderate	-	-	reasonable_with_monitoring	CYP2B6 reduced function may increase sertraline exposure in this prototype.
pgx_paroxetine_cyp2d6_um_v1	pgx	local fallback	paroxetine	cpic_sri_2023 moderate	-	-	reasonable_with_monitoring	CYP2D6 ultrarapid metabolism may lower exposure for some CYP2D6-substrate antidepressants.
pgx_paroxetine_cyp2d6_im_v1	pgx	local fallback	paroxetine	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	CYP2D6 intermediate metabolism creates modest exposure uncertainty.
pgx_fluoxetine_cyp2d6_um_v1	pgx	local fallback	fluoxetine	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	CYP2D6 ultrarapid metabolism may lower exposure for some CYP2D6-substrate antidepressants.
pgx_fluoxetine_cyp2d6_im_v1	pgx	local fallback	fluoxetine	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	CYP2D6 intermediate metabolism creates modest exposure uncertainty.
pgx_fluvoxamine_cyp2d6_um_v1	pgx	local fallback	fluvoxamine	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	CYP2D6 ultrarapid metabolism may lower exposure for some CYP2D6-substrate antidepressants.
pgx_fluvoxamine_cyp2d6_im_v1	pgx	local fallback	fluvoxamine	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	CYP2D6 intermediate metabolism creates modest exposure uncertainty.
pgx_venlafaxine_cyp2d6_um_v1	pgx	local fallback	venlafaxine	cpic_sri_2023 moderate	-	-	reasonable_with_monitoring	CYP2D6 ultrarapid metabolism may lower exposure for some CYP2D6-substrate antidepressants.
pgx_venlafaxine_cyp2d6_im_v1	pgx	local fallback	venlafaxine	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	CYP2D6 intermediate metabolism creates modest exposure uncertainty.
pgx_duloxetine_cyp2d6_um_v1	pgx	local fallback	duloxetine	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	CYP2D6 ultrarapid metabolism may lower exposure for some CYP2D6-substrate antidepressants.
pgx_duloxetine_cyp2d6_im_v1	pgx	local fallback	duloxetine	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	CYP2D6 intermediate metabolism creates modest exposure uncertainty.
pgx_vortioxetine_cyp2d6_um_v1	pgx	local fallback	vortioxetine	cpic_sri_2023 moderate	-	-	reasonable_with_monitoring	CYP2D6 ultrarapid metabolism may lower exposure for some CYP2D6-substrate antidepressants.
pgx_vortioxetine_cyp2d6_im_v1	pgx	local fallback	vortioxetine	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	CYP2D6 intermediate metabolism creates modest exposure uncertainty.
pgx_mirtazapine_cyp2d6_um_v1	pgx	local fallback	mirtazapine	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	CYP2D6 ultrarapid metabolism may lower exposure for some CYP2D6-substrate antidepressants.
pgx_mirtazapine_cyp2d6_im_v1	pgx	local fallback	mirtazapine	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	CYP2D6 intermediate metabolism creates modest exposure uncertainty.
pgx_amitriptyline_cyp2d6_um_v1	pgx	local fallback	amitriptyline	cpic_tca_2016 high	-	-	consider_alternative	CYP2D6 ultrarapid metabolism may lower TCA exposure and response probability.
pgx_nortriptyline_cyp2d6_um_v1	pgx	local fallback	nortriptyline	cpic_tca_2016 high	-	-	consider_alternative	CYP2D6 ultrarapid metabolism may lower TCA exposure and response probability.
pgx_imipramine_cyp2d6_um_v1	pgx	local fallback	imipramine	cpic_tca_2016 high	-	-	consider_alternative	CYP2D6 ultrarapid metabolism may lower TCA exposure and response probability.
pgx_clomipramine_cyp2d6_pm_v1	pgx	local fallback	clomipramine	cpic_tca_2016 high	-	-	consider_alternative	CYP2D6 poor metabolism may substantially increase TCA exposure in this prototype.
pgx_clomipramine_cyp2d6_um_v1	pgx	local fallback	clomipramine	cpic_tca_2016 high	-	-	consider_alternative	CYP2D6 ultrarapid metabolism may lower TCA exposure and response probability.
pgx_doxepin_cyp2d6_pm_v1	pgx	local fallback	doxepin	cpic_tca_2016 high	-	-	consider_alternative	CYP2D6 poor metabolism may substantially increase TCA exposure in this prototype.
pgx_doxepin_cyp2d6_um_v1	pgx	local fallback	doxepin	cpic_tca_2016 high	-	-	consider_alternative	CYP2D6 ultrarapid metabolism may lower TCA exposure and response probability.
pgx_amitriptyline_cyp2c19_um_v1	pgx	local fallback	amitriptyline	cpic_tca_2016 moderate	-	-	reasonable_with_monitoring	CYP2C19 rapid or ultrarapid metabolism may alter tertiary TCA exposure.
pgx_imipramine_cyp2c19_um_v1	pgx	local fallback	imipramine	cpic_tca_2016 moderate	-	-	reasonable_with_monitoring	CYP2C19 rapid or ultrarapid metabolism may alter tertiary TCA exposure.
pgx_clomipramine_cyp2c19_pm_v1	pgx	local fallback	clomipramine	cpic_tca_2016 high	-	-	use_with_caution	CYP2C19 poor metabolism may increase tertiary TCA exposure.
pgx_clomipramine_cyp2c19_um_v1	pgx	local fallback	clomipramine	cpic_tca_2016 moderate	-	-	reasonable_with_monitoring	CYP2C19 rapid or ultrarapid metabolism may alter tertiary TCA exposure.
pgx_doxepin_cyp2c19_pm_v1	pgx	local fallback	doxepin	cpic_tca_2016 high	-	-	use_with_caution	CYP2C19 poor metabolism may increase tertiary TCA exposure.
pgx_doxepin_cyp2c19_um_v1	pgx	local fallback	doxepin	cpic_tca_2016 moderate	-	-	reasonable_with_monitoring	CYP2C19 rapid or ultrarapid metabolism may alter tertiary TCA exposure.
pgx_bupropion_cyp2b6_intermediate_v1	pgx	local fallback	bupropion	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	CYP2B6 intermediate metabolism creates modest exposure uncertainty for bupropion.
combined_amitriptyline_cyp2d6_pm_cyp2c19_pm_v1	combined	local fallback	amitriptyline	cpic_tca_2016 high	-	-	clinical_review_required	Both CYP2D6 and CYP2C19 reduced-function results point toward higher TCA exposure risk.
combined_amitriptyline_cyp2d6_um_cyp2c19_um_v1	combined	local fallback	amitriptyline	cpic_tca_2016 high	-	-	consider_alternative	Both CYP2D6 and CYP2C19 increased-function results may lower TCA exposure.
combined_imipramine_cyp2d6_pm_cyp2c19_pm_v1	combined	local fallback	imipramine	cpic_tca_2016 high	-	-	clinical_review_required	Both CYP2D6 and CYP2C19 reduced-function results point toward higher TCA exposure risk.
combined_imipramine_cyp2d6_um_cyp2c19_um_v1	combined	local fallback	imipramine	cpic_tca_2016 high	-	-	consider_alternative	Both CYP2D6 and CYP2C19 increased-function results may lower TCA exposure.
combined_clomipramine_cyp2d6_pm_cyp2c19_pm_v1	combined	local fallback	clomipramine	cpic_tca_2016 high	-	-	clinical_review_required	Both CYP2D6 and CYP2C19 reduced-function results point toward higher TCA exposure risk.
combined_clomipramine_cyp2d6_um_cyp2c19_um_v1	combined	local fallback	clomipramine	cpic_tca_2016 high	-	-	consider_alternative	Both CYP2D6 and CYP2C19 increased-function results may lower TCA exposure.
combined_doxepin_cyp2d6_pm_cyp2c19_pm_v1	combined	local fallback	doxepin	cpic_tca_2016 high	-	-	clinical_review_required	Both CYP2D6 and CYP2C19 reduced-function results point toward higher TCA exposure risk.
combined_doxepin_cyp2d6_um_cyp2c19_um_v1	combined	local fallback	doxepin	cpic_tca_2016 high	-	-	consider_alternative	Both CYP2D6 and CYP2C19 increased-function results may lower TCA exposure.
combined_sertraline_cyp2c19_pm_cyp2b6_poor_v1	combined	local fallback	sertraline	cpic_sri_2023 moderate	-	-	use_with_caution	CYP2C19 poor metabolism plus reduced CYP2B6 activity may increase sertraline exposure uncertainty.
combined_citalopram_cyp2c19_pm_qt_v1	combined	local fallback	citalopram	fda_citalopram_label high	-	-	clinical_review_required	CYP2C19 poor metabolism and QT risk together create a higher-priority review for citalopram.
combined_escitalopram_cyp2c19_pm_qt_v1	combined	local fallback	escitalopram	cpic_sri_2023 high	-	-	clinical_review_required	CYP2C19 poor metabolism and QT risk together increase escitalopram review priority.
combined_paroxetine_cyp2d6_pm_strong_inhibitor_v1	combined	local fallback	paroxetine	mechanistic_cyp_pathways moderate	-	-	use_with_caution	A CYP2D6 inhibitor is present and functional CYP2D6 is already poor, so CYP2D6-substrate exposure uncertainty is higher.
combined_venlafaxine_cyp2d6_pm_strong_inhibitor_v1	combined	local fallback	venlafaxine	mechanistic_cyp_pathways moderate	-	-	use_with_caution	A CYP2D6 inhibitor is present and functional CYP2D6 is already poor, so CYP2D6-substrate exposure uncertainty is higher.
combined_vortioxetine_cyp2d6_pm_strong_inhibitor_v1	combined	local fallback	vortioxetine	mechanistic_cyp_pathways moderate	-	-	use_with_caution	A CYP2D6 inhibitor is present and functional CYP2D6 is already poor, so CYP2D6-substrate exposure uncertainty is higher.
combined_amitriptyline_cyp2d6_pm_strong_inhibitor_v1	combined	local fallback	amitriptyline	mechanistic_cyp_pathways moderate	-	-	use_with_caution	A CYP2D6 inhibitor is present and functional CYP2D6 is already poor, so CYP2D6-substrate exposure uncertainty is higher.
combined_nortriptyline_cyp2d6_pm_strong_inhibitor_v1	combined	local fallback	nortriptyline	mechanistic_cyp_pathways moderate	-	-	use_with_caution	A CYP2D6 inhibitor is present and functional CYP2D6 is already poor, so CYP2D6-substrate exposure uncertainty is higher.
combined_imipramine_cyp2d6_pm_strong_inhibitor_v1	combined	local fallback	imipramine	mechanistic_cyp_pathways moderate	-	-	use_with_caution	A CYP2D6 inhibitor is present and functional CYP2D6 is already poor, so CYP2D6-substrate exposure uncertainty is higher.
combined_clomipramine_cyp2d6_pm_strong_inhibitor_v1	combined	local fallback	clomipramine	mechanistic_cyp_pathways moderate	-	-	use_with_caution	A CYP2D6 inhibitor is present and functional CYP2D6 is already poor, so CYP2D6-substrate exposure uncertainty is higher.
combined_doxepin_cyp2d6_pm_strong_inhibitor_v1	combined	local fallback	doxepin	mechanistic_cyp_pathways moderate	-	-	use_with_caution	A CYP2D6 inhibitor is present and functional CYP2D6 is already poor, so CYP2D6-substrate exposure uncertainty is higher.
phenoconversion_cyp2d6_strong_inhibitor_v1	phenoconversion	local fallback	CYP2D6	mechanistic_cyp_pathways moderate	-	-	reasonable_with_monitoring	A strong CYP2D6 inhibitor in the medication list may reduce functional CYP2D6 activity.
phenoconversion_cyp2d6_moderate_inhibitor_v1	phenoconversion	local fallback	CYP2D6	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	A moderate CYP2D6 inhibitor may partially reduce functional CYP2D6 activity.
phenoconversion_cyp2c19_inhibitor_v1	phenoconversion	local fallback	CYP2C19	mechanistic_cyp_pathways low	-	-	reasonable_with_monitoring	A CYP2C19 inhibitor may reduce functional CYP2C19 activity.
safety_bupropion_seizure_history_hard_stop_v1	clinical_safety	local fallback	bupropion	dailymed_bupropion_label high	-	-	avoid	Seizure history is a high-priority safety concern for bupropion in this prototype.
safety_citalopram_qt_risk_v1	clinical_safety	local fallback	citalopram	fda_citalopram_label high	-	-	clinical_review_required	QT risk was entered, so medications with QT burden are downgraded for clinician review.
safety_escitalopram_qt_risk_v1	clinical_safety	local fallback	escitalopram	local_demo_rulebase_v2 moderate	-	-	use_with_caution	QT risk was entered, so medications with QT burden are downgraded for clinician review.
safety_amitriptyline_qt_risk_v1	clinical_safety	local fallback	amitriptyline	local_demo_rulebase_v2 moderate	-	-	clinical_review_required	QT risk was entered, so medications with QT burden are downgraded for clinician review.
safety_nortriptyline_qt_risk_v1	clinical_safety	local fallback	nortriptyline	local_demo_rulebase_v2 moderate	-	-	clinical_review_required	QT risk was entered, so medications with QT burden are downgraded for clinician review.
safety_imipramine_qt_risk_v1	clinical_safety	local fallback	imipramine	local_demo_rulebase_v2 moderate	-	-	clinical_review_required	QT risk was entered, so medications with QT burden are downgraded for clinician review.
safety_clomipramine_qt_risk_v1	clinical_safety	local fallback	clomipramine	local_demo_rulebase_v2 moderate	-	-	clinical_review_required	QT risk was entered, so medications with QT burden are downgraded for clinician review.
safety_doxepin_qt_risk_v1	clinical_safety	local fallback	doxepin	local_demo_rulebase_v2 moderate	-	-	clinical_review_required	QT risk was entered, so medications with QT burden are downgraded for clinician review.
safety_trazodone_qt_risk_v1	clinical_safety	local fallback	trazodone	local_demo_rulebase_v2 moderate	-	-	use_with_caution	QT risk was entered, so medications with QT burden are downgraded for clinician review.
safety_amitriptyline_overdose_risk_v1	clinical_safety	local fallback	amitriptyline	local_demo_rulebase_v2 moderate	-	-	clinical_review_required	TCA overdose toxicity risk makes this a clinical-review-required result in the prototype.
safety_nortriptyline_overdose_risk_v1	clinical_safety	local fallback	nortriptyline	local_demo_rulebase_v2 moderate	-	-	clinical_review_required	TCA overdose toxicity risk makes this a clinical-review-required result in the prototype.
safety_imipramine_overdose_risk_v1	clinical_safety	local fallback	imipramine	local_demo_rulebase_v2 moderate	-	-	clinical_review_required	TCA overdose toxicity risk makes this a clinical-review-required result in the prototype.
safety_clomipramine_overdose_risk_v1	clinical_safety	local fallback	clomipramine	local_demo_rulebase_v2 moderate	-	-	clinical_review_required	TCA overdose toxicity risk makes this a clinical-review-required result in the prototype.
safety_doxepin_overdose_risk_v1	clinical_safety	local fallback	doxepin	local_demo_rulebase_v2 moderate	-	-	clinical_review_required	TCA overdose toxicity risk makes this a clinical-review-required result in the prototype.
safety_ssri_bleeding_risk_v1	clinical_safety	local fallback	SSRI	local_demo_rulebase_v2 moderate	-	-	reasonable_with_monitoring	Bleeding-risk context or NSAID/anticoagulant medication was entered, so serotonergic antidepressants are flagged.
safety_snri_bleeding_risk_v1	clinical_safety	local fallback	SNRI	local_demo_rulebase_v2 moderate	-	-	reasonable_with_monitoring	Bleeding-risk context or NSAID/anticoagulant medication was entered, so serotonergic antidepressants are flagged.
safety_serotonin_modulator_bleeding_risk_v1	clinical_safety	local fallback	Serotonin Modulator	local_demo_rulebase_v2 moderate	-	-	reasonable_with_monitoring	Bleeding-risk context or NSAID/anticoagulant medication was entered, so serotonergic antidepressants are flagged.
safety_bipolar_mania_all_antidepressants_v1	clinical_safety	local fallback	global	local_demo_rulebase_v2 moderate	-	-	clinical_review_required	Bipolar/mania history was entered; antidepressant ranking requires clinician review in this prototype.
safety_citalopram_hepatic_impairment_v1	clinical_safety	local fallback	citalopram	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_escitalopram_hepatic_impairment_v1	clinical_safety	local fallback	escitalopram	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_sertraline_hepatic_impairment_v1	clinical_safety	local fallback	sertraline	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_fluoxetine_hepatic_impairment_v1	clinical_safety	local fallback	fluoxetine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_fluvoxamine_hepatic_impairment_v1	clinical_safety	local fallback	fluvoxamine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_paroxetine_hepatic_impairment_v1	clinical_safety	local fallback	paroxetine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_venlafaxine_hepatic_impairment_v1	clinical_safety	local fallback	venlafaxine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_duloxetine_hepatic_impairment_v1	clinical_safety	local fallback	duloxetine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_amitriptyline_hepatic_impairment_v1	clinical_safety	local fallback	amitriptyline	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_nortriptyline_hepatic_impairment_v1	clinical_safety	local fallback	nortriptyline	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_imipramine_hepatic_impairment_v1	clinical_safety	local fallback	imipramine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_clomipramine_hepatic_impairment_v1	clinical_safety	local fallback	clomipramine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_doxepin_hepatic_impairment_v1	clinical_safety	local fallback	doxepin	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_bupropion_hepatic_impairment_v1	clinical_safety	local fallback	bupropion	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_mirtazapine_hepatic_impairment_v1	clinical_safety	local fallback	mirtazapine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_vortioxetine_hepatic_impairment_v1	clinical_safety	local fallback	vortioxetine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_trazodone_hepatic_impairment_v1	clinical_safety	local fallback	trazodone	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Hepatic impairment was entered, reducing confidence/safety for hepatically cleared medications.
safety_venlafaxine_renal_impairment_v1	clinical_safety	local fallback	venlafaxine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Renal impairment was entered, reducing confidence/safety for medications with renal review needs.
safety_duloxetine_renal_impairment_v1	clinical_safety	local fallback	duloxetine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Renal impairment was entered, reducing confidence/safety for medications with renal review needs.
safety_desvenlafaxine_renal_impairment_v1	clinical_safety	local fallback	desvenlafaxine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Renal impairment was entered, reducing confidence/safety for medications with renal review needs.
safety_bupropion_renal_impairment_v1	clinical_safety	local fallback	bupropion	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Renal impairment was entered, reducing confidence/safety for medications with renal review needs.
safety_mirtazapine_renal_impairment_v1	clinical_safety	local fallback	mirtazapine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Renal impairment was entered, reducing confidence/safety for medications with renal review needs.
safety_pregnancy_lactation_all_v1	clinical_safety	local fallback	global	local_demo_rulebase_v2 low	-	-	clinical_review_required	Pregnancy/lactation context requires clinician review; this prototype does not rank reproductive safety.
safety_amitriptyline_elderly_fall_sedation_v1	clinical_safety	local fallback	amitriptyline	local_demo_rulebase_v2 low	-	-	use_with_caution	Fall/sedation risk was entered; sedating or anticholinergic medications are downgraded.
safety_nortriptyline_elderly_fall_sedation_v1	clinical_safety	local fallback	nortriptyline	local_demo_rulebase_v2 low	-	-	use_with_caution	Fall/sedation risk was entered; sedating or anticholinergic medications are downgraded.
safety_imipramine_elderly_fall_sedation_v1	clinical_safety	local fallback	imipramine	local_demo_rulebase_v2 low	-	-	use_with_caution	Fall/sedation risk was entered; sedating or anticholinergic medications are downgraded.
safety_clomipramine_elderly_fall_sedation_v1	clinical_safety	local fallback	clomipramine	local_demo_rulebase_v2 low	-	-	use_with_caution	Fall/sedation risk was entered; sedating or anticholinergic medications are downgraded.
safety_doxepin_elderly_fall_sedation_v1	clinical_safety	local fallback	doxepin	local_demo_rulebase_v2 low	-	-	use_with_caution	Fall/sedation risk was entered; sedating or anticholinergic medications are downgraded.
safety_mirtazapine_elderly_fall_sedation_v1	clinical_safety	local fallback	mirtazapine	local_demo_rulebase_v2 low	-	-	use_with_caution	Fall/sedation risk was entered; sedating or anticholinergic medications are downgraded.
safety_trazodone_elderly_fall_sedation_v1	clinical_safety	local fallback	trazodone	local_demo_rulebase_v2 low	-	-	use_with_caution	Fall/sedation risk was entered; sedating or anticholinergic medications are downgraded.
safety_serotonergic_combination_v1	clinical_safety	local fallback	global	local_demo_rulebase_v2 moderate	-	-	use_with_caution	A serotonergic current medication was entered, so serotonergic antidepressants receive a combination warning.
preference_amitriptyline_avoidSedation_v1	preference	local fallback	amitriptyline	local_demo_rulebase_v2 low	-	-	use_with_caution	Avoid sedation preference penalized sedating options.
preference_imipramine_avoidSedation_v1	preference	local fallback	imipramine	local_demo_rulebase_v2 low	-	-	use_with_caution	Avoid sedation preference penalized sedating options.
preference_clomipramine_avoidSedation_v1	preference	local fallback	clomipramine	local_demo_rulebase_v2 low	-	-	use_with_caution	Avoid sedation preference penalized sedating options.
preference_doxepin_avoidSedation_v1	preference	local fallback	doxepin	local_demo_rulebase_v2 low	-	-	use_with_caution	Avoid sedation preference penalized sedating options.
preference_mirtazapine_avoidSedation_v1	preference	local fallback	mirtazapine	local_demo_rulebase_v2 low	-	-	use_with_caution	Avoid sedation preference penalized sedating options.
preference_trazodone_avoidSedation_v1	preference	local fallback	trazodone	local_demo_rulebase_v2 low	-	-	use_with_caution	Avoid sedation preference penalized sedating options.
preference_paroxetine_avoidWeightGain_v1	preference	local fallback	paroxetine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid weight gain preference penalized medications with higher modeled weight-gain burden.
preference_amitriptyline_avoidWeightGain_v1	preference	local fallback	amitriptyline	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid weight gain preference penalized medications with higher modeled weight-gain burden.
preference_imipramine_avoidWeightGain_v1	preference	local fallback	imipramine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid weight gain preference penalized medications with higher modeled weight-gain burden.
preference_clomipramine_avoidWeightGain_v1	preference	local fallback	clomipramine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid weight gain preference penalized medications with higher modeled weight-gain burden.
preference_doxepin_avoidWeightGain_v1	preference	local fallback	doxepin	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid weight gain preference penalized medications with higher modeled weight-gain burden.
preference_mirtazapine_avoidWeightGain_v1	preference	local fallback	mirtazapine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid weight gain preference penalized medications with higher modeled weight-gain burden.
preference_citalopram_avoidSexualSideEffects_v1	preference	local fallback	citalopram	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid sexual side effects preference penalized medications with higher modeled sexual-side-effect burden.
preference_escitalopram_avoidSexualSideEffects_v1	preference	local fallback	escitalopram	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid sexual side effects preference penalized medications with higher modeled sexual-side-effect burden.
preference_sertraline_avoidSexualSideEffects_v1	preference	local fallback	sertraline	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid sexual side effects preference penalized medications with higher modeled sexual-side-effect burden.
preference_fluoxetine_avoidSexualSideEffects_v1	preference	local fallback	fluoxetine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid sexual side effects preference penalized medications with higher modeled sexual-side-effect burden.
preference_fluvoxamine_avoidSexualSideEffects_v1	preference	local fallback	fluvoxamine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid sexual side effects preference penalized medications with higher modeled sexual-side-effect burden.
preference_paroxetine_avoidSexualSideEffects_v1	preference	local fallback	paroxetine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid sexual side effects preference penalized medications with higher modeled sexual-side-effect burden.
preference_venlafaxine_avoidSexualSideEffects_v1	preference	local fallback	venlafaxine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid sexual side effects preference penalized medications with higher modeled sexual-side-effect burden.
preference_duloxetine_avoidSexualSideEffects_v1	preference	local fallback	duloxetine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid sexual side effects preference penalized medications with higher modeled sexual-side-effect burden.
preference_fluoxetine_avoidActivationAnxiety_v1	preference	local fallback	fluoxetine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid activation/anxiety preference penalized activating options.
preference_venlafaxine_avoidActivationAnxiety_v1	preference	local fallback	venlafaxine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid activation/anxiety preference penalized activating options.
preference_bupropion_avoidActivationAnxiety_v1	preference	local fallback	bupropion	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid activation/anxiety preference penalized activating options.
preference_sertraline_avoidNausea_v1	preference	local fallback	sertraline	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid nausea preference penalized medications with higher modeled nausea/GI burden.
preference_venlafaxine_avoidNausea_v1	preference	local fallback	venlafaxine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid nausea preference penalized medications with higher modeled nausea/GI burden.
preference_duloxetine_avoidNausea_v1	preference	local fallback	duloxetine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid nausea preference penalized medications with higher modeled nausea/GI burden.
preference_vortioxetine_avoidNausea_v1	preference	local fallback	vortioxetine	local_demo_rulebase_v2 low	-	-	reasonable_with_monitoring	Avoid nausea preference penalized medications with higher modeled nausea/GI burden.
preference_amitriptyline_avoidAnticholinergicEffects_v1	preference	local fallback	amitriptyline	local_demo_rulebase_v2 low	-	-	use_with_caution	Avoid anticholinergic effects preference penalized medications with high anticholinergic burden.
preference_nortriptyline_avoidAnticholinergicEffects_v1	preference	local fallback	nortriptyline	local_demo_rulebase_v2 low	-	-	use_with_caution	Avoid anticholinergic effects preference penalized medications with high anticholinergic burden.
preference_imipramine_avoidAnticholinergicEffects_v1	preference	local fallback	imipramine	local_demo_rulebase_v2 low	-	-	use_with_caution	Avoid anticholinergic effects preference penalized medications with high anticholinergic burden.
preference_clomipramine_avoidAnticholinergicEffects_v1	preference	local fallback	clomipramine	local_demo_rulebase_v2 low	-	-	use_with_caution	Avoid anticholinergic effects preference penalized medications with high anticholinergic burden.
preference_doxepin_avoidAnticholinergicEffects_v1	preference	local fallback	doxepin	local_demo_rulebase_v2 low	-	-	use_with_caution	Avoid anticholinergic effects preference penalized medications with high anticholinergic burden.
preference_mirtazapine_prefer_sleep_help_v1	preference	local fallback	mirtazapine	local_demo_rulebase_v2 low	-	-	reasonable	Preference for sleep help modestly improved this drug's preference-fit dimension.
preference_trazodone_prefer_sleep_help_v1	preference	local fallback	trazodone	local_demo_rulebase_v2 low	-	-	reasonable	Preference for sleep help modestly improved this drug's preference-fit dimension.
preference_doxepin_prefer_sleep_help_v1	preference	local fallback	doxepin	local_demo_rulebase_v2 low	-	-	reasonable	Preference for sleep help modestly improved this drug's preference-fit dimension.
preference_bupropion_prefer_energizing_v1	preference	local fallback	bupropion	local_demo_rulebase_v2 low	-	-	reasonable	Preference for an energizing profile modestly improved this drug's preference-fit dimension.
preference_fluoxetine_prefer_energizing_v1	preference	local fallback	fluoxetine	local_demo_rulebase_v2 low	-	-	reasonable	Preference for an energizing profile modestly improved this drug's preference-fit dimension.
preference_venlafaxine_prefer_energizing_v1	preference	local fallback	venlafaxine	local_demo_rulebase_v2 low	-	-	reasonable	Preference for an energizing profile modestly improved this drug's preference-fit dimension.
contraindication_ssri_maoi_combination_v1	contraindication	local fallback	SSRI	local_demo_rulebase_v2 moderate	-	-	avoid	A current MAOI/MAOI-like medication was entered, so serotonergic antidepressants are placed in avoid for this prototype pending clinician review.
contraindication_snri_maoi_combination_v1	contraindication	local fallback	SNRI	local_demo_rulebase_v2 moderate	-	-	avoid	A current MAOI/MAOI-like medication was entered, so serotonergic antidepressants are placed in avoid for this prototype pending clinician review.
contraindication_tca_maoi_combination_v1	contraindication	local fallback	TCA	local_demo_rulebase_v2 moderate	-	-	avoid	A current MAOI/MAOI-like medication was entered, so serotonergic antidepressants are placed in avoid for this prototype pending clinician review.
contraindication_serotonin_modulator_maoi_combination_v1	contraindication	local fallback	Serotonin Modulator	local_demo_rulebase_v2 moderate	-	-	avoid	A current MAOI/MAOI-like medication was entered, so serotonergic antidepressants are placed in avoid for this prototype pending clinician review.
contraindication_bupropion_eating_disorder_v1	contraindication	local fallback	bupropion	dailymed_bupropion_label high	-	-	avoid	Eating-disorder history is a high-priority bupropion safety concern in this prototype.

ClinPGx generated rule trace

21 generated PGx rules, with source object IDs and local fallback supersession metadata where applicable.

clinpgx_amitriptyline_cyp2c19_poor_guideline_high_fixture_cpic_tca_cyp2c19_amitriptyline_pm

amitriptyline · CYP2C19 · poor

Source object: fixture-cpic-tca-cyp2c19-amitriptyline-pm · guideline_annotation · guideline_high

No import review flag · Supersedes pgx_amitriptyline_cyp2c19_pm_v1

clinpgx_amitriptyline_cyp2d6_poor_guideline_high_fixture_cpic_tca_cyp2d6_amitriptyline_pm

amitriptyline · CYP2D6 · poor

Source object: fixture-cpic-tca-cyp2d6-amitriptyline-pm · guideline_annotation · guideline_high

No import review flag · Supersedes pgx_amitriptyline_cyp2d6_pm_v1

clinpgx_bupropion_cyp2b6_poor_clinical_annotation_fixture_clinical_bupropion_cyp2b6_pm

bupropion · CYP2B6 · poor

Source object: fixture-clinical-bupropion-cyp2b6-pm · clinical_annotation · clinical_annotation

No import review flag · Supersedes pgx_bupropion_cyp2b6_poor_v1

clinpgx_citalopram_cyp2c19_poor_guideline_high_fixture_cpic_sri_cyp2c19_citalopram_pm

citalopram · CYP2C19 · poor

Source object: fixture-cpic-sri-cyp2c19-citalopram-pm · guideline_annotation · guideline_high

No import review flag · Supersedes pgx_citalopram_cyp2c19_pm_v1

clinpgx_citalopram_cyp2c19_rapid_guideline_moderate_fixture_cpic_sri_cyp2c19_citalopram_rapid

citalopram · CYP2C19 · rapid

Source object: fixture-cpic-sri-cyp2c19-citalopram-rapid · guideline_annotation · guideline_moderate

No import review flag

clinpgx_citalopram_cyp2c19_ultrarapid_guideline_high_fixture_cpic_sri_cyp2c19_citalopram_um

citalopram · CYP2C19 · ultrarapid

Source object: fixture-cpic-sri-cyp2c19-citalopram-um · guideline_annotation · guideline_high

No import review flag · Supersedes pgx_citalopram_cyp2c19_um_v1

clinpgx_duloxetine_cyp2d6_poor_clinical_annotation_fixture_clinical_duloxetine_cyp2d6_pm

duloxetine · CYP2D6 · poor

Source object: fixture-clinical-duloxetine-cyp2d6-pm · clinical_annotation · clinical_annotation

No import review flag · Supersedes pgx_duloxetine_cyp2d6_pm_v1

clinpgx_escitalopram_cyp2c19_poor_guideline_high_fixture_cpic_sri_cyp2c19_escitalopram_pm

escitalopram · CYP2C19 · poor

Source object: fixture-cpic-sri-cyp2c19-escitalopram-pm · guideline_annotation · guideline_high

No import review flag · Supersedes pgx_escitalopram_cyp2c19_pm_v1

clinpgx_escitalopram_cyp2c19_ultrarapid_guideline_high_fixture_cpic_sri_cyp2c19_escitalopram_um

escitalopram · CYP2C19 · ultrarapid

Source object: fixture-cpic-sri-cyp2c19-escitalopram-um · guideline_annotation · guideline_high

No import review flag · Supersedes pgx_escitalopram_cyp2c19_um_v1

clinpgx_fluoxetine_cyp2d6_poor_clinical_annotation_fixture_clinical_fluoxetine_cyp2d6_pm

fluoxetine · CYP2D6 · poor

Source object: fixture-clinical-fluoxetine-cyp2d6-pm · clinical_annotation · clinical_annotation

No import review flag · Supersedes pgx_fluoxetine_cyp2d6_pm_v1

clinpgx_fluvoxamine_cyp2d6_poor_pathway_fixture_pathway_fluvoxamine_cyp2d6

fluvoxamine · CYP2D6 · poor

Source object: fixture-pathway-fluvoxamine-cyp2d6 · pathway · pathway

Requires review · Supersedes pgx_fluvoxamine_cyp2d6_pm_v1

clinpgx_imipramine_cyp2c19_poor_guideline_high_fixture_cpic_tca_cyp2c19_imipramine_pm

imipramine · CYP2C19 · poor

Source object: fixture-cpic-tca-cyp2c19-imipramine-pm · guideline_annotation · guideline_high

No import review flag · Supersedes pgx_imipramine_cyp2c19_pm_v1

clinpgx_imipramine_cyp2d6_poor_guideline_high_fixture_cpic_tca_cyp2d6_imipramine_pm

imipramine · CYP2D6 · poor

Source object: fixture-cpic-tca-cyp2d6-imipramine-pm · guideline_annotation · guideline_high

No import review flag · Supersedes pgx_imipramine_cyp2d6_pm_v1

clinpgx_mirtazapine_cyp2d6_poor_pathway_fixture_pathway_mirtazapine_cyp2d6

mirtazapine · CYP2D6 · poor

Source object: fixture-pathway-mirtazapine-cyp2d6 · pathway · pathway

Requires review · Supersedes pgx_mirtazapine_cyp2d6_pm_v1

clinpgx_nortriptyline_cyp2d6_poor_guideline_high_fixture_cpic_tca_cyp2d6_nortriptyline_pm

nortriptyline · CYP2D6 · poor

Source object: fixture-cpic-tca-cyp2d6-nortriptyline-pm · guideline_annotation · guideline_high

No import review flag · Supersedes pgx_nortriptyline_cyp2d6_pm_v1

clinpgx_paroxetine_cyp2d6_poor_clinical_annotation_fixture_clinical_paroxetine_cyp2d6_pm

paroxetine · CYP2D6 · poor

Source object: fixture-clinical-paroxetine-cyp2d6-pm · clinical_annotation · clinical_annotation

No import review flag · Supersedes pgx_paroxetine_cyp2d6_pm_v1

clinpgx_sertraline_cyp2b6_poor_guideline_moderate_fixture_cpic_sri_cyp2b6_sertraline_pm

sertraline · CYP2B6 · poor

Source object: fixture-cpic-sri-cyp2b6-sertraline-pm · guideline_annotation · guideline_moderate

No import review flag · Supersedes pgx_sertraline_cyp2b6_poor_v1

clinpgx_sertraline_cyp2c19_poor_guideline_moderate_fixture_cpic_sri_cyp2c19_sertraline_pm

sertraline · CYP2C19 · poor

Source object: fixture-cpic-sri-cyp2c19-sertraline-pm · guideline_annotation · guideline_moderate

No import review flag · Supersedes pgx_sertraline_cyp2c19_poor_v1

clinpgx_sertraline_cyp2c19_ultrarapid_guideline_moderate_fixture_cpic_sri_cyp2c19_sertraline_um

sertraline · CYP2C19 · ultrarapid

Source object: fixture-cpic-sri-cyp2c19-sertraline-um · guideline_annotation · guideline_moderate

No import review flag · Supersedes pgx_sertraline_cyp2c19_ultrarapid_v1

clinpgx_venlafaxine_cyp2d6_poor_clinical_annotation_fixture_clinical_venlafaxine_cyp2d6_pm

venlafaxine · CYP2D6 · poor

Source object: fixture-clinical-venlafaxine-cyp2d6-pm · clinical_annotation · clinical_annotation

No import review flag · Supersedes pgx_venlafaxine_cyp2d6_pm_v1

20 local PGx fallback rule(s) are retained in files but superseded at runtime by generated ClinPGx-backed rules.